So 36 hours after Ocrevus was approved and not a blip of question or concern on here? Let's face it, we will be on the outside looking in.
Biogen has up to a 24% royalty, but its been estimated by various research firms on Wall Street that it will eat into 10-20% of total sales of BIIB's existing Tysabri sales. Its likely net-loss in revenue. Watch out for Celgene's MS drug that should get approval next year in 2018. That along with this new Roche approval will be a solid 1-2 punch that BIIB never faced before.
I'd like to personally thank George for selling this asset off instead of keeping it in house. Good call?.....not so much.
